ProKidney (NASDAQ:PROK) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
ProKidney (NASDAQ:PROK) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
ProKidney GAAP EPS of -$0.12 beats by $0.02, revenue of $0.22M beats by $0.18M [Seeking Alpha]
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates [Yahoo! Finance]
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates